Publications by authors named "Michelle D Hackshaw"

Claim this Profile
R
Retrospective Observational Study of Outcomes in HER2-Positive Metastatic Breast Cancer (mBC) Patients Treated with Ado-Trastuzumab Emtansine (T-DM1) and Subsequent Treatments After T-DM1 in the United States.
Neelima Denduluri, Janet L Espirito, Michelle D Hackshaw, Chuck Wentworth, Tamy Recchia

Drugs Real World Outcomes· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient preferences for features of HER2-targeted treatment of advanced or metastatic breast cancer: a discrete-choice experiment study.
Carol Mansfield, Willings Botha, Gerard T Vondeling, Kathleen Klein, Kongming Wang, Michelle D Hackshaw

Breast Cancer· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Incidence of adverse events with therapies targeting HER2-positive metastatic breast cancer: a literature review.
Edith A Perez, Chau Dang, Caleb Lee, Jasmeet Singh, Kongming Wang, Michelle D Hackshaw

Breast Cancer Res Treat· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Health-related quality of life in women with breast cancer: a review of measures.
Maribel Salas, Margaret Mordin, Colleen Castro, Zahidul Islam, Nora Tu, Michelle D Hackshaw

BMC Cancer· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic factors of brain metastasis and survival among HER2-positive metastatic breast cancer patients: a systematic literature review.
Michelle D Hackshaw, Heather E Danysh, Mackenzie Henderson, Eric Wang, Nora Tu

BMC Cancer· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Review of Survival, Safety, and Clinical Outcomes in HER2+ Metastatic Gastric Cancer Following the Administration of Trastuzumab.
Michelle D Hackshaw, Christine L Bui, Amy Ladner, Nora Tu, Zahidul Islam

Cancer Treat Res Commun· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Incidence of pneumonitis/interstitial lung disease induced by HER2-targeting therapy for HER2-positive metastatic breast cancer.
Michelle D Hackshaw, Heather E Danysh, Jasmeet Singh, Mary E Ritchey, Amy Ladner

Breast Cancer Res Treat· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prescribing Preferences in the First-Line Treatment for Patients With Metastatic Renal Cell Carcinoma in the United States.
Michelle D Hackshaw, Michael Holmes, Maria Lankford, Michele Thomas, Augustina Ogbonnaya

Clin Genitourin Cancer· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Systematic Literature Review of Adverse Events Associated with Systemic Treatments Used in Advanced Soft Tissue Sarcoma.
Ann Colosia, Shahnaz Khan, Michelle D Hackshaw, Alan Oglesby, James A Kaye

Sarcoma· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quality-adjusted time without symptoms or toxicity analysis of pazopanib versus sunitinib in patients with renal cell carcinoma.
Jennifer L Beaumont, John M Salsman, Jose Diaz, Keith C Deen, Lauren McCann, Michelle D Hackshaw

Cancer· April 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patterns of Care in Patients with Metastatic Renal Cell Carcinoma Among a U.S. Payer Population with Commercial or Medicare Advantage Membership.
Lesley-Ann Miller, Stephen Stemkowski, Kim Saverno, Daniel C Lane, Zhuliang Tao, Michelle D Hackshaw

J Manag Care Spec Pharm· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Authors Respond.
Ryan N Hansen, Michelle D Hackshaw, Sean D Sullivan, Scott D Ramsey

J Manag Care Spec Pharm· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-Line and Sequential Use of Pazopanib Followed by Mammalian Target of Rapamycin Inhibitor Therapy Among Patients With Advanced Renal Cell Carcinoma in a US Community Oncology Setting.
Nicholas J Vogelzang, Michelle D Hackshaw, Thomas E Hutson, Debajyoti Bhowmik, Mark Yap

Clin Genitourin Cancer· June 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Persistence and compliance among U.S. patients receiving pazopanib or sunitinib as first-line therapy for advanced renal cell carcinoma: a retrospective claims analysis.
Stacey A DaCosta Byfield, Jeffrey T McPheeters, Tanya M Burton, Saurabh P Nagar, Michelle D Hackshaw

J Manag Care Spec Pharm· June 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Health care costs among renal cancer patients using pazopanib and sunitinib.
Ryan N Hansen, Michelle D Hackshaw, Saurabh P Nagar, Bhakti Arondekar, Keith C Deen

J Manag Care Spec Pharm· January 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness of pazopanib versus sunitinib for renal cancer in the United States.
Thomas E Delea, Jordan Amdahl, Jose Diaz, Hamid Reza Nakhaipour, Michelle D Hackshaw

J Manag Care Spec Pharm· January 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Persistence and compliance with pazopanib in patients with advanced renal cell carcinoma within a U.S. administrative claims database.
Michelle D Hackshaw, Saurabh P Nagar, Daniel C Parks, Lesley-Ann N Miller

J Manag Care Spec Pharm· June 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Epidemiology, treatment patterns, and outcomes of metastatic soft tissue sarcoma in a community-based oncology network.
Clara Chen, Rohit Borker, James Ewing, Wan-Yu Tseng, Michelle D Hackshaw

Sarcoma· March 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Costs Associated with Intravenous Cancer Therapy Administration in Patients with Metastatic Soft Tissue Sarcoma in a US Population.
Mei Sheng Duh, Michelle D Hackshaw, Jasmina I Ivanova, Gregory Kruse, Lesley-Ann N Miller

Sarcoma· January 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Economic burden of selected adverse events in patients aged ≥65 years with metastatic renal cell carcinoma.
May Hagiwara, Michelle D Hackshaw, Gerry Oster

J Med Econ· November 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pazopanib versus sunitinib in metastatic renal-cell carcinoma.
Robert J Motzer, Thomas E Hutson, David Cella, James Reeves, Robert Hawkins, Michelle D Hackshaw

N Engl J Med· August 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Retrospective US database analysis of drug utilization patterns, health care resource use, and costs associated with adjuvant interferon alfa-2b therapy for treatment of malignant melanoma following surgery.
Michelle D Hackshaw, Arun Krishna, David J Mauro

Clinicoecon Outcomes Res· October 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis